Previous research has shown that SARS-CoV-2 infection could activate TGF-β signaling and oxidative overload, and the neuropathological pathways causing tau hyperphosphorylation typically associated with AD were activated in COVID-19 patients [45]. This evidence concerns the gene MAPT and Alzheimer disease.